Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check5 days agoChange DetectedRevision updated to v3.0.2 (replacing v3.0.1); the 'Back to Top' link/button was removed.SummaryDifference0.2%
- Check12 days agoChange DetectedThe web page has been updated to include information on Type 2 diabetes under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference0.5%
- Check19 days agoChange DetectedThe web page has been updated to include new drug information for ipragliflozin and specific details about the facility's location in Seongnam-si, Gyeonggi-do, South Korea, while removing previous references to Metformin and other related topics.SummaryDifference5%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has been updated to version 2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.